Combination treatment with olaparib and anticancer agents that disrupt HR repair such as ATR inhibitors (ATRi) or CHK1 inhibitors (CHK1i) may therefore represent an effective strategy to sensitize ovarian cancer cells to olaparib. Here, CHEK1 is linked to ovarian cancer.